brolucizumab: Clinical Trials

42 trials of brolucizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

30 completed, 7 terminated, 2 withdrawn, 1 active not recruiting. 22 Phase 3, 5 Phase 4, 2 Not applicable, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 322Completed 16, Terminated 3, Withdrawn 2, Unknown 1
Phase 45Completed 4, Terminated 1
Not applicable2Active not recruiting 1, Not yet recruiting 1
Phase 21Completed 1

Follow brolucizumab: new trials by email Literature Review of brolucizumab trials Research Report on brolucizumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Intensive Glycemic Control Combined With Brolucizumab for Diabetic Macular Edema
Intensive Glycemic Management, Brolucizumab - Diabetic Macular Edema, Diabetic Retinopathy
Not applicableNot yet recruitingThe Fourth Affiliated Hospital of Zhejiang University School of Medicine1002026-11-302026-11-13
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
brolucizumab - Diabetic Macular Edema
Phase 4CompletedNovartis Pharmaceuticals662024-12-112026-04-13
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
Brolucizumab 6mg - Macular Polypoidal Choroidal Vasculopathy (PCV)
Phase 3CompletedNovartis Pharmaceuticals1482023-02-062025-12-15
Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy
Brolucizumab Injection [Beovu] - Age-Related Macular Degeneration, Pachychoroid Neovasculopathy
Phase 3UnknownYeungnam University College of Medicine362023-01-012023-01-05
Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
Beovu - Diabetic Macular Edema
CompletedNovartis Pharmaceuticals2222022-09-022025-06-13
Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E
Brolucizumab, Aflibercept - Age-Related Macular Degeneration
Phase 4CompletedThe University of Hong Kong302022-07-252024-05-08
Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
Aflibercept, Brolucizumab, early treat and extend (T&E) - Wet Age-related Macular Degeneration
Not applicableActive not recruitingBerner Augenklinik802022-05-092025-12-08
Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting
Brolucizumab - Neovascular Age-related Macular Degeneration
TerminatedNovartis Pharmaceuticals32022-04-132025-01-13
Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice
brolucizumab - Neovascular Age-related Macular Degeneration
TerminatedNovartis Pharmaceuticals3022021-11-192024-10-29
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
Brolucizumab - Neovascular Age-related Macular Degeneration
Phase 4CompletedNovartis Pharmaceuticals1222021-10-152025-05-16
Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion
Brolucizumab - Intraocular Inflammation, Retinal Vascular Occlusion
CompletedNovartis Pharmaceuticals1982021-08-232022-12-20
Regulatory Post-Marketing Surveillance Study for Brolucizumab
brolucizumab - Neovascular Age-related Macular Degeneration
CompletedNovartis Pharmaceuticals33692021-08-182026-11-06
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
Brolucizumab - Age-related Macular Degeneration
Phase 4CompletedNovartis Pharmaceuticals522021-07-132025-09-26
Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
brolucizumab - Age-related Macular Degeneration (AMD)
Phase 3WithdrawnNovartis Pharmaceuticals2021-05-312021-09-23
Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal
Brolucizumab - Neovascular Age-related Macular Degeneration (nAMD)
TerminatedNovartis Pharmaceuticals812021-05-102025-03-25
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
brolucizumab, ranibizumab, aflibercept - Neovascular Age-Related Macular Degeneration
CompletedNovartis Pharmaceuticals4942021-02-232024-06-18
Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Brolucizumab, Aflibercept - Diabetic Macula Edema
Phase 3WithdrawnNovartis Pharmaceuticals2021-02-012021-03-04
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
RTH258/Brolucizumab - Neovascular Age Related Macular Degeneration
Phase 3CompletedNovartis Pharmaceuticals2102021-01-262024-10-09
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
brolucizumab - Neovascular Age-related Macular Degeneration
Phase 3CompletedNovartis Pharmaceuticals2482020-12-162024-10-09
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
RTH258/Brolucizumab - Neovascular Age-Related Macular Degeneration
Phase 3CompletedNovartis Pharmaceuticals2952020-12-142024-11-07

Showing 20 of 42. Sign in to see all of them.

Conditions studied

Macular Degeneration (16)  ·  Vision Disorders (9)  ·  Choroidal Neovascularization (8)  ·  Wet Macular Degeneration (7)  ·  Macular Edema (6)  ·  Geographic Atrophy (5)  ·  Diabetic Retinopathy (4)  ·  Eye Diseases (4)  ·  Retinal Diseases (4)  ·  Retinal Degeneration (3)  ·  Retinal Vein Occlusion (3)  ·  Neurofibromatosis 2 (1)  ·  Polypoidal Choroidal Vasculopathy (1)  ·  Retinal Neovascularization (1)  ·  Retinal Vasculitis (1)

Sponsors

Novartis Pharmaceuticals (34)  ·  Alcon Research (3)  ·  Berner Augenklinik (1)  ·  The Fourth Affiliated Hospital of Zhejiang University School of Medicine (1)  ·  The University of Hong Kong (1)  ·  Vista Klinik (1)  ·  Yeungnam University College of Medicine (1)

Countries

United States (15)  ·  Germany (8)  ·  Puerto Rico (8)  ·  Switzerland (8)  ·  France (7)  ·  Italy (7)  ·  Canada (6)  ·  Israel (6)  ·  Japan (6)  ·  South Korea (6)  ·  Spain (6)  ·  Australia (5)  ·  China (5)  ·  Czechia (5)  ·  Taiwan (5)

Top investigators

Justus G. Garweg, Prof. Dr. med. (1)  ·  Katja Hatz, PD Dr. med (1)  ·  Nadia Zakaria, MD (1)

Results publications

PMID 30986442, PMID 33207259, PMID 34968756, PMID 37343623, PMID 39033924, PMID 35188581, PMID 35301822, PMID 37971723, PMID 38360182, PMID 40833455, PMID 42024409, PMID 42082322, PMID 42492647

NIH funding

2019 (5), 2017 (2), 2018 (2), 2014 (1)